TGFB1 and idiopathic pulmonary fibrosis: Another agent, pirfenidone an antifibrotic agent that inhibits TGF-b mediated collagen synthesis, has also been approved by the FDA for treatment of IPF after the ASCEND trial demonstrated a reduced disease progression.